
PaySign Inc (PAYS) Stock Forecast & Price Target
PaySign Inc (PAYS) Analyst Ratings
Bulls say
PaySign is a rapidly growing payment processing and prepaid card company, evidenced by its strong 2Q results with 48% revenue growth and 113% increase in adjusted EBITDA. The company's focus on pharmaceutical and healthcare industries, strong financial position, and recent acquisition of Gamma contribute to its positive outlook, although competition and regulatory compliance remain concerns. With plans for international expansion and development of patient affordability programs, Paysign has the potential for continued success and diversification.
Bears say
PaySign is facing several risks as a niche payment solutions provider, including a competitive market dominated by larger competitors, potential regulatory changes that could affect their operations, reliance on a small number of bank partners, and concentration in the plasma donor compensation niche. Additionally, the company's insider ownership and low float may lead to higher share price volatility. While their financials have been strong, particularly in the pharmaceutical segment, there may be challenges in maintaining and growing market share.
This aggregate rating is based on analysts' research of PaySign Inc and is not a guaranteed prediction by Public.com or investment advice.
PaySign Inc (PAYS) Analyst Forecast & Price Prediction
Start investing in PaySign Inc (PAYS)
Order type
Buy in
Order amount
Est. shares
0 shares